Vadadustat

Drug Profile

Vadadustat

Alternative Names: AKB-6548; MT 6548; PG-1016548

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Procter & Gamble
  • Developer Akebia Therapeutics; Mitsubishi Tanabe Pharma Corporation
  • Class Antianaemics; Chlorophenols; Pyridines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 10 Aug 2017 Akebia Therapeutics plans the TRILO2GY phase III trial for Anaemia in USA (NCT03242967)
  • 09 Aug 2017 Akebia Therapeutics plans the phase III TRILO2GY trial
  • 23 May 2017 Akebia Therapeutics initiates the FO2RWARD phase II trial in Anaemia in USA (NCT03140722)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top